Proving efficacy of birch allergen subcutaneous immunotherapy is challenging due to the numerous factors influencing birch pollen allergen exposure in field studies.
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| INTRODUCTION
Birch is the most allergenic tree pollen in north, central and eastern Europe and the major pollen allergen-producing tree in northern Europe. 1 The abundance of birch trees is highest in northern and eastern Europe, decreasing towards southern and western Europe. 2, 3 This correlates with the prevalence of sensitization, with low prevalence in southern Europe and high prevalence in northern Europe 4 ;
approximately 15% of the population in northern Europe are sensitized to birch pollen allergens. 5 Allergen immunotherapy is, to date, the only causal treatment option for allergic rhinoconjunctivitis with the potential to modify the natural course of allergic disease. 6, 7 Very few double-blind placebo-controlled (DBPC) studies have demonstrated efficacy for birch pollen immunotherapy, either sublingually 4 or subcutaneously. [8] [9] [10] Proving efficacy of birch pollen immunotherapy in field studies is challenging due to the peculiarities of birch pollination and the nature of quantifying pollen exposure. In addition, symptoms depend more on birch allergen content than on the amount of pollen, as well as on patient sensitivity to specific birch allergens. [11] [12] [13] Previous studies looking at efficacy of birch pollen subcutaneous immunotherapy (SCIT) have been conducted over a 1-to 2-year treatment period and involved mostly a single geographic location for pollen collection. 8, 10, 14 This trial evaluates the safety and efficacy of SCIT using a birch pollen allergoid preparation 2 | ME TH ODS
| Trial design
The trial was designed as a multi-national, multi-centre, randomized, 
| Patients
The study included patients aged 18-60 years with IgE-mediated moderate to severe seasonal allergic rhinitis/rhinoconjunctivitis 16 with or without allergic bronchial asthma to birch pollen allergens (Global Initiative for Asthma [GINA] grade I or II). 17 Birch pollen allergy was documented as described in the Appendix S1. A patient diary was used to document allergy symptoms and use of rescue medication. Prior to start of the birch pollen season, patients were issued permitted rescue medication (see Appendix S1).
| Allergen immunotherapy

| Pollen counts
Each study centre was linked to one or two regional pollen count stations. Information on atmospheric pollen load was supplied by the European Aeroallergen Network (EAN). The respective birch pollen loads were measured for each region for each of the 3 study years, and onset of each birch pollen season was determined by the sponsor, based on EAN data.
| Assessment of efficacy
Patients recorded their daily symptoms and medication intake for 8 weeks during the birch pollen season, and a Symptom Medication Score (SMS) was calculated as previously described. 19 Evaluation of the SMS comprised the 7 days before and 13 days after the day of 
| Safety measures
Safety parameters collected included adverse events (AEs), clinical chemistry and haematology parameters. Adverse events were assessed for their relationship to treatment and coded using the Medical Dictionary for Regulatory Activities. 3 | RESULTS
| Patients
In total, 403 patients were screened and 253 patients were randomized into the study. The disposition of patients is shown in Figure 2 .
In the Safety Analysis Set (SAF), demographics and screening characteristics showed no remarkable differences between the two treatment groups, including comparable frequency of birch allergy symptoms (eg, allergic asthma: active 27.0%, placebo 23.0%), sex Sweden. Figure 3 illustrates the course of the pollen count for the FAS and FAS-NE, over the three pollen seasons.
| Pollen count
| Efficacy
Patients in the DBPC phase who received at least one dose of study medication and for whom the efficacy assessment of the primary variable was available for at least 1 year were included in the FAS (n = 227). After 2 years of treatment (primary endpoint), a positive trend was observed: active-treated patients in the FAS had a reduction in SMS of 15.2% (LS-mean) compared with placebo-treated patients, although the significance level of 5% was not achieved (P = 0.0710; Figure 4 and Table 2 ). For the Per-Protocol Set (PPS, n = 216, post hoc analysis) patients with major protocol violations were excluded (including possible allergy to a range of other allergens causing symptoms in and around the birch pollen season-alder, hazel, poplar, elm, willow-tree, beech, oak, ash, rape, Dermatophagoides pteronyssinus, Dermatophagoides farinae, dog, cat, Aspergillus, Penicillium). The comparison of active vs placebo in the PPS after 2 years of treatment consolidated the positive trend observed in the FAS (16.7% reduction, LSmean), but again a significance level of 5% level was not achieved (P = 0.0523). However, the SMS of the active-treated patients of the FAS-NE (n = 102) was significantly lower compared to the placebo group after 2 years of treatment (P = 0.0034; Figure 4 and Table 2 ).
These results were associated with a clinically relevant difference in SMS between active and placebo of 32.7% (LS-mean). After 3 years of treatment, during the OLP of the study, the mean SMS of the activetreated patients of the FAS, PPS and FAS-NE had decreased further from the second year (Table 2) , despite an increasing birch pollen load ( Figure 3 ). The analysis of the first year data (secondary endpoint) did not reveal a significant difference in SMS of active-vs placebo-treated patients for any analysis sets (FAS, PPS and FAS-NE; Table 2) . The analysis of the number of "well days" and the immunologic changes in the patients were other secondary objectives of this study. In the FAS, the median number of "well days" during the 21-day evaluation period of birch pollen flight in 2007 was higher in the active treatment group (42.9%, n = 100) compared to the placebo group (19.0%, n = 91) but not statistically significant (P = 0.1062).
However, in the FAS-NE, this increase was significant (active 61.9%, n = 47; placebo 28.6%, n = 42; P = 0.0232; Figure 5 ). After 3 years of active treatment (OLP in 2008), the median number of "well days"
improved to 61.9% in the FAS (n = 73) and 71.4% FAS-NE (n = 35).
In the FAS and FAS-NE, median IgG 4 and IgG 1 levels increased significantly (P < 0.001) in favour of the active treatment group after the first and second preseasonal treatment courses and continued to rise in the third year of treatment ( Figure S2 ). Median IgG 4 and IgG 1 levels of the placebo group remained largely unchanged during the entire study period.
| Tolerability and safety
All patients who received at least one dose of the study medication During the DBPC phase, 61 of 122 patients (50.0%) in the active treatment group and 37 of 127 patients (29.1%) in the placebo treatment group experienced at least 1 AE with a suspected relationship to study medication. During the DBPC phase, the most common AEs (occurring in >4% of patients in either treatment group) with a suspected relationship to study medication were injection site reaction, injection site pruritus, injection site swelling, injection site pain, rhinitis, injection site erythema and conjunctivitis ( despite the pollen counts having dropped to low levels ( Figure S1 ).
This effect was also seen in another birch pollen study 14 but has not been observed in grass pollen studies. 20, 25 As discussed above for the second year of treatment, interfering allergens may be responsible.
Strong variability of the annual birch pollen count, as seen in this study, is a well-known phenomenon 24, 26, 27 reported previously. 8, 9, 14 In seasons with a low pollen load, that is, 2007 when the primary endpoint was estimated, placebo-treated patients may have no symptoms or need of rescue medication (as seen in minimum SMS values of 0 in Table 2 ). This makes it difficult to show a significant difference in the SMS between active-and placebo-treated patients.
In a study stratifying study centres according to the disease severity of the placebo group, active-treated patients from centres with low symptom severity in the placebo group showed no or only limited treatment benefit. 28 In this same study, for active-treated patients from centres with placebo groups with medium or severe symptom levels, a clinically relevant difference between active-and placebotreated patients could be demonstrated, indicating that treatment efficacy may be underestimated if a study includes too many centres with low pollen exposure and low disease severity. Previous field studies have failed to show a difference in SMS between active-and placebo-treated patients in seasons with low birch pollen loads, 9,14 yet demonstrated significant efficacy in seasons with higher birch pollen. 4, 9, 14 In this study, the SMS and birch pollen counts courses showed differences, which are normally not observed in grass pollen studies. 20, 25 Importantly, the average counting error of Hirst-type pollen traps used in Europe is ≥25% 29 and, because they are usually mounted at rooftop level, may not accurately reflect the pollen exposure of a moving person at street level. 30, 31 It is assumed that data from a pollen sampler typically represent the pollen load within a certain area with similar vegetation and climate. 29 However, significant discrepancies in pollen counts (mainly due to differences in local vegetation) have been known among pollen traps located within a 30-kilometre radius. 32 In another study, deviations in pollen concentration from 283% to 1962% were measured among pollen samplers located a few kilometres from each other. 30 In Germany, some study centres and pollen-monitoring stations were located up to 94 km apart and patients may live even more distant. The distribution of birch trees in central Europe is patchy and presents local differences, whereas in northern Europe birch trees are the most abundant and cover the area continuously. 2, 30 All pollen monitoring stations in Sweden, Finland and Poland were located in the same town or within 18 km of the study centre and therefore may better reflect patients' actual pollen exposure. Collection of local or patient individualized data on pollen concentrations may result in more reliable data on pollen exposure in clinical trials. 30, 32 Nevertheless, personalized methods are still under development and local pollen samplers cannot capture differences in pollen exposure due to patients' lifestyle or spatial movements. 30, 32 Even if birch pollen counts are representative of a patient's local environment, they serve only as a proxy for actual allergen exposure. [33] [34] [35] A comparable pollen load provokes different levels of symptom severity in different regions and years. 36 Up to 10-fold daily, [33] [34] [35] >fivefold yearly, and threefold regional differences in the release of the major allergen Bet v 1 from birch pollen have been reported, and numerous local factors influence its release. comparability of chamber studies to field studies needs still to be confirmed.
This trial was performed without a baseline phase, which has implications for treatment allocation and documentation of clinical efficacy. 21 Patients' recall of their medical condition in the previous season may be subject to memory bias. Therefore, patients who do not experience the appropriate minimum of symptoms could have been included, which risks biasing the treatment groups. 21, 39 In fact, the range of median SMS (minimum-maximum) of placebo-treated patients indicates that patients with no or very little symptoms were included in the study (2006-2007, Table 2 ). Furthermore, nonresponders to treatment may have been among the evaluated study population because there is no option to detect them without a baseline phase. 21 In conclusion, although the primary endpoint was not reached Indeed, the clinical efficacy of Allergovit ® Birch in allergic rhinitis has been confirmed using an environmental challenge chamber, 40 suggesting that the non-attainment of a 5% significance level in the FAS and PPS in this study may be due to environmental factors.
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